Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEOPATTRA: Coramitug (NNC6019-0001) vs placebo in ATTR cardiomyopathy
CTR20260419Phase 3Active
- Sponsor
- Novo Nordisk
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of coramitug in amyloidotic transthyretin cardiomyopathy (ATTR-CM), sponsored by Novo Nordisk. Started May 2026; status: active.
02
Drugs
coramitug
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on CTR20260419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260419.